◼ Archived
Business
🔮 holds ✗
Amgen drops ph. 1 obesity drug, upping pressure on MariTide
Amgen's decision to drop an obesity drug in phase 1 trials has intensified competition in the pharmaceutical sector.
Amgen
3 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Amgen
This hub groups 3 separate news trends connected to Amgen, spanning June 26, 2026 through August 5, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 24 article observations and 24 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
Roche's KRAS G12C inhibitor, divarasib, outperformed rival therapies in a head-to-head Phase 3 trial for lung cancer.
◼ Archived
Business
🔮 fades ✓
European Regulator Calls for Amgen’s Tavneos to Have Authorization Revoked
European regulators are recommending the revocation of marketing authorization for Amgen's autoimmune disease drug, Tavneos.